Markarian, NM, Galli, G, Patel, D, Hemmings, M, Nagpal, P, Berghuis, AM et al.. Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency. Front Microbiol. 2022;13 :933983. doi: 10.3389/fmicb.2022.933983. PubMed PMID:35847101 PubMed Central PMC9283111.
Blaye, C, Darbo, É, Debled, M, Brouste, V, Vélasco, V, Pinard, C et al.. An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. ESMO Open. 2022;7 (4):100502. doi: 10.1016/j.esmoop.2022.100502. PubMed PMID:35759853 PubMed Central PMC9434232.
Iaxx, R, Lefort, F, Domblides, C, Ravaud, A, Bernhard, JC, Gross-Goupil, M et al.. An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives. Ther Clin Risk Manag. 2022;18 :619-632. doi: 10.2147/TCRM.S251673. PubMed PMID:35677148 PubMed Central PMC9169675.
Heraudet, L, Delon, T, Veillon, R, Vergnenègre, C, Lepetit, H, Daste, A et al.. Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non-small cell lung cancer: A retrospective study. Thorac Cancer. 2022;13 (9):1391-1400. doi: 10.1111/1759-7714.14403. PubMed PMID:35434866 PubMed Central PMC9058314.
Blaye, C, Boyer, T, Peyraud, F, Domblides, C, Larmonier, N. Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast Cancers. Front Immunol. 2022;13 :838040. doi: 10.3389/fimmu.2022.838040. PubMed PMID:35309358 PubMed Central PMC8927658.
Gefard-Gontier, E, Markich, R, Zysman, M, Veillon, R, Daste, A, Domblides, C et al.. Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors. Cancer Immunol Immunother. 2022;71 (11):2609-2618. doi: 10.1007/s00262-022-03180-x. PubMed PMID:35305123 .